Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue - PubMed (original) (raw)
. 2017 Jul 1;3(7):921-927.
doi: 10.1001/jamaoncol.2016.6374.
Reiko Nishihara 2, Yin Cao 3, Mingyang Song 3, Kosuke Mima 4, Zhi Rong Qian 4, Jonathan A Nowak 5, Keisuke Kosumi 4, Tsuyoshi Hamada 4, Yohei Masugi 4, Susan Bullman 4, David A Drew 1, Aleksandar D Kostic 6, Teresa T Fung 7, Wendy S Garrett 8, Curtis Huttenhower 9, Kana Wu 10, Jeffrey A Meyerhardt 4, Xuehong Zhang 11, Walter C Willett 12, Edward L Giovannucci 13, Charles S Fuchs 14, Andrew T Chan 15, Shuji Ogino 16
Affiliations
- PMID: 28125762
- PMCID: PMC5502000
- DOI: 10.1001/jamaoncol.2016.6374
Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue
Raaj S Mehta et al. JAMA Oncol. 2017.
Erratum in
- Incomplete Conflict of Interest Disclosures.
[No authors listed] [No authors listed] JAMA Oncol. 2019 Apr 1;5(4):579. doi: 10.1001/jamaoncol.2019.0286. JAMA Oncol. 2019. PMID: 30844032 Free PMC article. No abstract available.
Abstract
Importance: Fusobacterium nucleatum appears to play a role in colorectal carcinogenesis through suppression of the hosts' immune response to tumor. Evidence also suggests that diet influences intestinal F nucleatum. However, the role of F nucleatum in mediating the relationship between diet and the risk of colorectal cancer is unknown.
Objective: To test the hypothesis that the associations of prudent diets (rich in whole grains and dietary fiber) and Western diets (rich in red and processed meat, refined grains, and desserts) with colorectal cancer risk may differ according to the presence of F nucleatum in tumor tissue.
Design, setting, and participants: A prospective cohort study was conducted using data from the Nurses' Health Study (June 1, 1980, to June 1, 2012) and the Health Professionals Follow-up Study (June 1, 1986, to June 1, 2012) on a total of 121 700 US female nurses and 51 529 US male health professionals aged 30 to 55 years and 40 to 75 years, respectively (both predominantly white individuals), at enrollment. Data analysis was performed from March 15, 2015, to August 10, 2016.
Exposures: Prudent and Western diets.
Main outcomes and measures: Incidence of colorectal carcinoma subclassified by F nucleatum status in tumor tissue, determined by quantitative polymerase chain reaction.
Results: Of the 173 229 individuals considered for the study, 137 217 were included in the analysis, 47 449 were male (34.6%), and mean (SD) baseline age for men was 54.0 (9.8) years and for women, 46.3 (7.2) years. A total of 1019 incident colon and rectal cancer cases with available F nucleatum data were documented over 26 to 32 years of follow-up, encompassing 3 643 562 person-years. The association of prudent diet with colorectal cancer significantly differed by tissue F nucleatum status (P = .01 for heterogeneity); prudent diet score was associated with a lower risk of F nucleatum-positive cancers (P = .003 for trend; multivariable hazard ratio of 0.43; 95% CI, 0.25-0.72, for the highest vs the lowest prudent score quartile) but not with F nucleatum-negative cancers (P = .47 for trend, the corresponding multivariable hazard ratio of 0.95; 95% CI, 0.77-1.17). There was no significant heterogeneity between the subgroups in relation to Western dietary pattern scores.
Conclusions and relevance: Prudent diets rich in whole grains and dietary fiber are associated with a lower risk for F nucleatum-positive colorectal cancer but not F nucleatum-negative cancer, supporting a potential role for intestinal microbiota in mediating the association between diet and colorectal neoplasms.
Conflict of interest statement
Conflict of interest: Dr Chan served as a consultant for Bayer Healthcare, Aralez Pharmaceuticals, Pfizer Inc., and PLx Pharma. This study was not funded by Bayer Healthcare, Aralez Pharmaceuticals, Pfizer Inc., or PLx Pharma. Dr Huttenhower serves as a consultant for Evelo Biosciences. No other conflict of interest exists. The other authors declare that they have no conflicts of interest.
Comment in
- Omitted Disclosures of Potential Conflicts of Interest in Articles Published in JAMA Oncology.
Fuchs CS. Fuchs CS. JAMA Oncol. 2019 Apr 1;5(4):578-579. doi: 10.1001/jamaoncol.2019.0235. JAMA Oncol. 2019. PMID: 30844040 No abstract available.
Similar articles
- Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum.
Liu L, Tabung FK, Zhang X, Nowak JA, Qian ZR, Hamada T, Nevo D, Bullman S, Mima K, Kosumi K, da Silva A, Song M, Cao Y, Twombly TS, Shi Y, Liu H, Gu M, Koh H, Li W, Du C, Chen Y, Li C, Li W, Mehta RS, Wu K, Wang M, Kostic AD, Giannakis M, Garrett WS, Hutthenhower C, Chan AT, Fuchs CS, Nishihara R, Ogino S, Giovannucci EL. Liu L, et al. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1622-1631.e3. doi: 10.1016/j.cgh.2018.04.030. Epub 2018 Apr 24. Clin Gastroenterol Hepatol. 2018. PMID: 29702299 Free PMC article. - Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Mima K, et al. JAMA Oncol. 2015 Aug;1(5):653-61. doi: 10.1001/jamaoncol.2015.1377. JAMA Oncol. 2015. PMID: 26181352 Free PMC article. - An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk.
Wang K, Lo CH, Mehta RS, Nguyen LH, Wang Y, Ma W, Ugai T, Kawamura H, Ugai S, Takashima Y, Mima K, Arima K, Okadome K, Giannakis M, Sears CL, Meyerhardt JA, Ng K, Segata N, Izard J, Rimm EB, Garrett WS, Huttenhower C, Giovannucci EL, Chan AT, Ogino S, Song M. Wang K, et al. Gastroenterology. 2024 Dec;167(7):1371-1383.e4. doi: 10.1053/j.gastro.2024.07.040. Epub 2024 Aug 6. Gastroenterology. 2024. PMID: 39117122 - Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Nosho K, et al. World J Gastroenterol. 2016 Jan 14;22(2):557-66. doi: 10.3748/wjg.v22.i2.557. World J Gastroenterol. 2016. PMID: 26811607 Free PMC article. Review. - Fusobacterium's link to colorectal neoplasia sequenced: A systematic review and future insights.
Hussan H, Clinton SK, Roberts K, Bailey MT. Hussan H, et al. World J Gastroenterol. 2017 Dec 28;23(48):8626-8650. doi: 10.3748/wjg.v23.i48.8626. World J Gastroenterol. 2017. PMID: 29358871 Free PMC article. Review.
Cited by
- Guideline for designing microbiome studies in neoplastic diseases.
Mikó E, Sipos A, Tóth E, Lehoczki A, Fekete M, Sebő É, Kardos G, Bai P. Mikó E, et al. Geroscience. 2024 Oct;46(5):4037-4057. doi: 10.1007/s11357-024-01255-4. Epub 2024 Jun 26. Geroscience. 2024. PMID: 38922379 Free PMC article. Review. - Human gut microbiota in health and disease: Unveiling the relationship.
Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM. Afzaal M, et al. Front Microbiol. 2022 Sep 26;13:999001. doi: 10.3389/fmicb.2022.999001. eCollection 2022. Front Microbiol. 2022. PMID: 36225386 Free PMC article. Review. - The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review.
Ranjbar M, Salehi R, Haghjooy Javanmard S, Rafiee L, Faraji H, Jafarpor S, Ferns GA, Ghayour-Mobarhan M, Manian M, Nedaeinia R. Ranjbar M, et al. Cancer Cell Int. 2021 Apr 6;21(1):194. doi: 10.1186/s12935-021-01886-z. Cancer Cell Int. 2021. PMID: 33823861 Free PMC article. Review. - Utilization of the microbiome in personalized medicine.
Ratiner K, Ciocan D, Abdeen SK, Elinav E. Ratiner K, et al. Nat Rev Microbiol. 2024 May;22(5):291-308. doi: 10.1038/s41579-023-00998-9. Epub 2023 Dec 18. Nat Rev Microbiol. 2024. PMID: 38110694 Review. - Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes.
Perillo F, Amoroso C, Strati F, Giuffrè MR, Díaz-Basabe A, Lattanzi G, Facciotti F. Perillo F, et al. Int J Mol Sci. 2020 Jul 29;21(15):5389. doi: 10.3390/ijms21155389. Int J Mol Sci. 2020. PMID: 32751239 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
- R35 CA197735/CA/NCI NIH HHS/United States
- R01 CA118553/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- P30 DK043351/DK/NIDDK NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- R01 CA202704/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- P30 DK036836/DK/NIDDK NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- R01 CA154426/CA/NCI NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- R01 CA169141/CA/NCI NIH HHS/United States
- K07 CA188126/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- K07 CA190673/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical